PMC:7289100 / 40899-41228
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T122 | 40-45 | Body_part | denotes | serum | http://purl.org/sig/ont/fma/fma63083 |
| T123 | 49-55 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
| T124 | 146-152 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
| T125 | 156-161 | Body_part | denotes | serum | http://purl.org/sig/ont/fma/fma63083 |
LitCovid-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T52 | 40-45 | Body_part | denotes | serum | http://purl.obolibrary.org/obo/UBERON_0001977 |
| T53 | 156-161 | Body_part | denotes | serum | http://purl.obolibrary.org/obo/UBERON_0001977 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T489 | 76-93 | Disease | denotes | rheumatic disease | http://purl.obolibrary.org/obo/MONDO_0005554 |
| T490 | 229-237 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T491 | 229-233 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T303 | 49-55 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
| T304 | 146-152 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
| T305 | 313-316 | http://purl.obolibrary.org/obo/CLO_0053794 | denotes | 4/1 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T165 | 293-302 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T250 | 0-329 | Sentence | denotes | Furthermore, an attempt to evaluate HCQ serum or plasma levels from various rheumatic disease patients receiving this treatment, found that these plasma or serum levels were unlikely to achieve the concentration shown to inhibit SARS-CoV-2 in vitro (average target 0.48 mg/L as opposed to the antiviral target of 4/1 mg/L) [113]. |
LitCovid-PMC-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T548 | 40-45 | UBERON:0001977 | denotes | serum |
| T549 | 49-55 | UBERON:0001969 | denotes | plasma |
| T550 | 146-152 | UBERON:0001969 | denotes | plasma |
| T551 | 156-161 | UBERON:0001977 | denotes | serum |
| T552 | 229-239 | SP_7 | denotes | SARS-CoV-2 |
| T32541 | 40-45 | UBERON:0001977 | denotes | serum |
| T46521 | 49-55 | UBERON:0001969 | denotes | plasma |
| T58589 | 146-152 | UBERON:0001969 | denotes | plasma |
| T99545 | 156-161 | UBERON:0001977 | denotes | serum |
| T13337 | 229-239 | SP_7 | denotes | SARS-CoV-2 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1343 | 94-102 | Species | denotes | patients | Tax:9606 |
| 1344 | 229-239 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 1363 | 36-39 | Chemical | denotes | HCQ | MESH:D006886 |
| 1377 | 76-93 | Disease | denotes | rheumatic disease | MESH:D012216 |